Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GM stuffit
WNC tanker starting to bounce here
haha
walls...right....right...
smartass!
sounds to me like they are trying to effect ribonuclease activity in the translation/transcription processes. This method would rely on mutagen nucleic acid sequences to be lethal genes to be effective.
it may be effective in stopping cancers, but my thought is this would only effect some cancers and not be a panacea.
translation: I think this stock has limited upside potential unless it has other drugs in the pipeline
good afternoon all...first day of school here...a little hectic...
SL...mortgage insurers taking a rest today
RDN 7.82
PMI 2.47
DJIA +100
hey
bored here...writing a journal summary of an anesthesia article for a position I'm applying for...
pictures?...
hope everyone is having a nice day off...
Futures
North/Latin America
INDEX VALUE CHANGE OPEN HIGH LOW TIME
DJIA INDEX 10,603.00 +40.00 10,554.00 10,605.00 10,548.00 11:28
S&P 500 1,136.90 +4.60 1,131.20 1,137.10 1,129.50 11:29
NASDAQ 100 1,874.00 +11.75 1,862.50 1,874.50 1,860.25 11:28
Futures
North/Latin America
INDEX VALUE CHANGE OPEN HIGH LOW TIME
DJIA INDEX 10,603.00 +40.00 10,554.00 10,605.00 10,548.00 11:28
S&P 500 1,136.90 +4.60 1,131.20 1,137.10 1,129.50 11:29
NASDAQ 100 1,874.00 +11.75 1,862.50 1,874.50 1,860.25 11:28
Hope you guys are having a nice day off
getting ready for school's start tomm; dad here at the house; we may go out later
I see djia futures +40...lets hope asia europe green tonight... will be nice for tomm
talk to you all tomm
congrats
Next Week's Events:
MONDAY
Earnings: MARKETS CLOSED;
Other: World Future Energy Summit
TUESDAY
Earnings: Before - C, FHN, FRX, PETS, AMTD ; After - CREE, CSX, IBM
Other: Special election to fill Kennedy's Seat, NJ Gov. Christie Inauguration Day, NY Boat Show, Exxon-Mobil-XTO Merger Hearing in DC
WEDNESDAY
Earnings: Before - BAC, BK, COH, MS, MI, NTRS, WFC, USB, STT ; After - EBAY, STX, SBUX
Other: Building Permits, PPI, Housing Starts, Crude Inventories ; Obama 1 Year in Office, Visa Shareholders Meeting,Berkshire Shareholder Meeting, Citi CFO Speaks on Fixed Income, Exxon-Mobil-XTO Merger Hearing in DC, NY Boat Show
THURSDAY
Earnings: Before - CAL, FITB, GS, KEY, LM, LUV, UNP, UNH, XRX ; After - AMD, AXP, GOOG
Other: Initial Claims, Leading Indicators, Philly Fed ; 30th Anniversary of Gold Peak (inflation adjusted high for gold of $2287 per oz)
FRIDAY
Earnings: Before - BBT, EXC, GE, HOG, KMB, SLB, STI
good afternoon
CRDC getting a pop here
I thought they already had limits?
stepping back a little
HEB +11% on this:
Hemispherx Biopharma Addresses Ampligen(R) CFS Preclinical Issues
9:46a ET January 14, 2010 (GlobeNewswire)
Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company") stated that on January 14, 2010, the Company submitted reports of new preclinical data regarding Ampligen (Poly I: Poly C12U), an experimental therapeutic being developed for potential treatment of Chronic Fatigue Syndrome ("CFS"), to the Food and Drug Administration ("FDA"). Hemispherx management believes these reports should be sufficient to address certain preclinical issues referenced in periodic reports filed by the Company with the Securities and Exchange Commission ("SEC"), including, most recently, the Company's Form 10-Q filed with the SEC on November 9, 2009, as well as in a Complete Response Letter from the FDA described in a December 1, 2009 press release. The preclinical studies discussed in these reports are the combined work-product of the staffs at Hemispherx and its subcontractor, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
The new preclinical data showed no evidence of antibodies against Ampligen(R) in primates and no evidence of an increase in certain undesirable cytokines (specific modulators of the immune system) at clinically used doses of Ampligen(R) for CFS. Although most other experimental immunomodulators have been associated with one or more features of aberrant immune activity, including toll-like receptor activators (of which Ampligen(R) is one), this was specifically not seen with Ampligen(R) in primates.
both RDN PMI down a couple % from yesterday's mini bounces
back now...DJIA +12
DJIA +22
GM all
just waking up....have to run to my sister's to get the weimeraner...will be back in an hour...
RIG 92.85
POT 117.37
FSLR 134.99
been watching this little play AEN the last few days...starts off slow...here at 1.20...usually ends the day at/close to 1.30...fwiw
that's the plan
later all
have a goodnight
I hear you...
biotech happy, huh?
yw...GL today
RDN PMI both were good today...
what are you in?
nope
clairmont is a neighborhood on St. Croix....North Shore...
RDN PMI both both nice bounces from days lows...
I like the mortgage insurance sector this year...despite what the conservative goldman analysts say...
great. will do.
GL
Good Afternoon BB
hope you had a good holidays
the lobster and some of us are
starting up the lotto board again...:
http://investorshub.advfn.com/boards/board.aspx?board_id=7793
stop by...we appreciate your opinion...
also...I've been busy with school/clinical rotations lately..will have some free time soon..we should get together for drinks..
thx...you should stop by...
BBL...
I have to mail a letter...I'm trying to get this Hopkins anesthesia position for next semester worked out...should be on the road within the week...
Nice catamaran lol
CYCC news from this AM:
Cyclacel Completes Previously Announced Registered Direct Offering
1:36p ET January 13, 2010 (GlobeNewswire)
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today that it completed its previously announced registered direct offering through the sale of shares of its common stock and warrants for gross proceeds of $7.2 million, before deducting placement agent fees and offering expenses, in a registered direct offering with select institutional investors. The offer included the sale and issuance of 2.85 million units, each unit consisting of one share of the Company's common stock and a warrant to purchase 0.25 shares of common stock, at a purchase price of $2.51 per unit. The warrants, which represent the right to acquire an aggregate of 712,500 shares of common stock at an exercise price of $3.26 per share, have a five-year term from the date of issuance and are exercisable beginning six months after the date of issuance.
The units were offered and sold pursuant to a prospectus supplement dated January 11, 2010 and an accompanying prospectus dated February 12, 2007, pursuant to the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission.
Roth Capital Partners, LLC served as the sole placement agent for the offering. Merriman Curhan Ford served as financial advisor.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the final prospectus supplement together with the accompanying prospectus can be obtained at the SEC's website at http://www.sec.gov or from Roth Capital Partners, LLC at 24 Corporate Plaza, Newport Beach, CA 92660.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans to submit a Special Protocol Assessment (SPA) request for a pivotal study with sapacitabine during the first quarter of 2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an Aurora kinase and VEGFR2 inhibitor, is in a Phase 1 trial in patients with solid tumors. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the U.S. Xclair(R) Cream for radiation dermatitis, Numoisyn(R) Liquid and Numoisyn(R) Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates. Please visit www.cyclacel.com for additional information.
Risk factors
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2008, as supplemented by the interim quarterly reports, filed with the SEC.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Cyclacel Pharmaceuticals, Inc.
CONTACT: Cyclacel Pharmaceuticals, Inc.
Investors/Media:
Corey Sohmer
(908) 517-7330
csohmer@cyclacel.com
PMI nice mini bounce
CYCC selling off now
Good afternoon all